Medicine
Binosto 91.37 mg effervescent tablet
Binosto 91.37 mg effervescent tablet is a prescription medicine containing Alendronate for oral use, marketed by Radius Health, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Alendronate
- Brand
- Binosto
- Strength
- 91.37 mg
- Dosage form
- Effervescent tablet
- Route
- Oral
- Packs
- 4 blister pack
- Marketing authorisation holder
- Radius Health
- Manufacturer
- Radius Health
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F), Protect from moisture. Store tablets in original blister package until use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 March 2012
- Identifiers
- RxCUI 1248077, 1248083DailyMed set ID 09765234-01bc-40f7-b9bb-c167056f3909NDC 70539-400Application NDA202344
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 blister pack in 1 box / 1 tablet, effervescent in 1 blister pack | 70539-400-04 | Radius Health | 12 March 2012 |
| 4 blister pack in 1 box / 1 tablet, effervescent in 1 blister pack | 70539-400-94 | Radius Health | 12 March 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 September 1995 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Alendronate
Clinical summary
Alendronate is a bisphosphonate indicated for treatment and prevention of osteoporosis in postmenopausal women, among other approved uses. It is available as tablets, oral solution and effervescent tablets. MedsAcross supplies Alendronate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AlendronateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- FOSAMAX prescribing information (Organon) · U.S. National Library of Medicine, DailyMed
Need Binosto 91.37 mg effervescent tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.